CH
CHY.F ChemoMetec A/S
- Market cap
- EUR 1.64B
- P/E
- 60.9x
- P/B
- 17.11x
- ROE
- 27.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CHY.F undervalued?
Graham numberThe Graham number of ChemoMetec A/S cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ChemoMetec A/S fundamental analysis
No fundamental analysis for ChemoMetec A/S yet.
ChemoMetec A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer;…
Full company profileChemoMetec A/S financial statements
ChemoMetec A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 90.3M | 113M | 176M | 214M | 281M | 428M | 444M | 408M | 496M | 511M |
| Gross Profit | 80.2M | 99.5M | 159M | 194M | 253M | 384M | 395M | 368M | 466M | 486M |
| Operating Income | 10.2M | 24.3M | 54.0M | 77.2M | 117M | 203M | 231M | 169M | 237M | 251M |
| EBITDA | 15.4M | 30.0M | 65.3M | 92.5M | 133M | 225M | 252M | 194M | 247M | 289M |
| Net Income | 7.49M | 18.2M | 41.8M | 59.2M | 88.4M | 159M | 179M | 136M | 175M | 202M |
| EPS | 0.43 | 1.19 | 2.66 | 3.40 | 5.08 | 9.16 | 10 | 7.83 | 10 | 12 |
| Balance Sheet | ||||||||||
| Total Assets | 97.6M | 114M | 238M | 263M | 345M | 501M | 658M | 677M | 828M | 861M |
| Total Liabilities | 33.2M | 41.0M | 64.9M | 60.4M | 79.9M | 144M | 125M | 111M | 155M | 136M |
| Shareholders' Equity | 64.4M | 73.0M | 173M | 203M | 265M | 357M | 533M | 565M | 673M | 725M |
| Cash & Short-term Investments | 12.4M | 9.78M | 98.2M | 96.9M | 150M | 209M | 317M | 296M | 342M | 290M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 9.76M | 25.4M | 58.3M | 72.0M | 108M | 177M | 154M | 129M | 207M | 210M |
| Capital Expenditure | 3.04M | 5.51M | 15.2M | 14.3M | 11.2M | 39.1M | 21.2M | 43.5M | 64.7M | 96.4M |
| Free Cash Flow | -833K | 8.97M | 31.2M | 45.3M | 83.3M | 121M | 113M | 85.5M | 143M | 114M |
| Ratios | ||||||||||
| ROE | 11.6% | 24.9% | 24.1% | 29.2% | 33.3% | 44.6% | 33.5% | 24.1% | 25.9% | 27.8% |
| ROA | 7.7% | 16.0% | 17.6% | 22.5% | 25.6% | 31.8% | 27.2% | 20.1% | 21.1% | 23.4% |
| Net Profit Margin | 8.3% | 16.2% | 23.8% | 27.6% | 31.4% | 37.2% | 40.2% | 33.4% | 35.3% | 39.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ChemoMetec A/S dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 60.4%
- Ex-dividend date
- Oct 10, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | DKK 122M | 7.04 | 60.4% |
| 2025 | DKK 69.6M | 4.00 | 39.8% |
| 2024 | DKK 104M | 6.00 | 76.6% |
| 2023 | - | - | - |
| 2022 | DKK 69.6M | 4.00 | 43.7% |
| 2021 | DKK 26.1M | 1.50 | 29.5% |
| 2020 | EUR 136M | 7.81 | 229.8% |
| 2019 | EUR 136M | 8.63 | 325.0% |
| 2018 | EUR 136M | 8.85 | 746.5% |
| 2017 | EUR 136M | 7.81 | 1,816.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ChemoMetec A/S
- Insiders 3.73%
- Institutions 52.41%
- Public & others 43.86%
- Shares outstanding 17.2M
- Free float 16.5M
ChemoMetec A/S company profile
- Company name
- ChemoMetec A/S
- Ticker
- CHY.F
- ISIN
- DK0060055861
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 174
- Fiscal year end
- June
- Address
- Gydevang 43, Allerød, Denmark, 3450
- Phone
- 45 48 13 10 20
- Website
- chemometec.com
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
ChemoMetec A/S management
6- Mr. Martin Helbo BehrensChief Executive Officer · born 1992
- Mr. Phillip Massie PriceChief Financial Officer · born 1992
- Mr. Bo Melholt NielsenChief Technology & Automation Officer
- Mr. Christopher Runchel M.Sc., Ph.D.Chief Sales Officer
- Mr. Søren KjærulffHead of R&D
- Emil SondergaardChief Commercial Officer